RxDoctor Payments Data

John Rachoy, DPM

Podiatrist · Munster, INNPI 1124138805

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (38.7%), education and travel and lodging — rather than concentrated in one kind of arrangement. 30 manufacturers reported payments, led by Arthrex at 37.8% of the total. Reporting peaked in 2019 at $10,534 and has fallen 69.3% since, to $3,229 in 2025. Among podiatrist clinicians in IN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$21,124in general payments, 2019–2025

Across 270 payments — averaging $78.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Arthrex$8K
  • Stryker$8K
  • Medwest Associates$2K
  • Organogenesis Inc.$920
  • Smith+Nephew$397
  • Orthofix Medical, Inc.$366
  • plus $2K from 24 others

What the payments were for

  • Travel & lodging$5,79027%
  • Food & beverage$8,18039%
  • Education$6,71932%
  • Gifts$4352%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$21,124 in reported general payments places this provider in the 90th percentile of 131 podiatrist providers in Indiana.

See all podiatrist providers in Indiana

Medicare billing

Part B allowed, 2024
$1,061,835
Medicare patients
536
Services billed
4,120

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SantylCollagenase Clostridium Hist.12$4,282
Gabapentin127$1,340
Etodolac41$1,044
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen74$863
Methylprednisolone120$604
Terbinafine Hcl77$562
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav65$533
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip21$424
Clotrimazole25$424
Pregabalin19$281
Clindamycin Hcl18$236
Doxycycline Hyclate19$189
Ciprofloxacin Hcl22$71
Tramadol Hcl14$48

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Smith+NephewSantyl$397$4,28212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 131 podiatrist providers in Indiana.

Other podiatrist in Munster

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →